I read the trials, the FDA announcements, and the specialty-society statements so you don't have to — and then I tell you, in plain English, what's actually approved, what's promising, and what's still a maybe. Here's my current map of where the evidence stands, with every source linked.
A quick word on how I sort this page, because the difference matters: FDA-approved means a drug in this class earned a formal indication after full review — that's the highest bar there is. Growing use and early research mean clinicians and researchers are genuinely interested, but the proof isn't in yet. I'll never blur those lines for you. Anyone who does is selling something.
This one made me sit up: tirzepatide is the first medication ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity, per the FDA's announcement. Mom translation: the 2 a.m. gasping-awake problem now has a prescription option that isn't a machine on your nightstand.
Source: FDAIn people with established heart disease, GLP-1 therapy cuts the risk of major cardiac events by roughly a fifth — and researchers increasingly think part of that benefit isn't about the weight loss at all. If heart disease runs in your family, this is the card I'd want you to remember.
Source: U.S. NewsIn diabetic chronic kidney disease, a GLP-1 reduced major kidney events by about a quarter and slowed the loss of kidney function — enough for its own FDA indication. Kidneys don't complain until they're in real trouble, which is exactly why this finding matters.
Source: U.S. NewsA GLP-1 is now approved for MASH — the serious form of fatty liver disease — with moderate-to-advanced scarring, after trials showed genuine improvement in inflammation and fibrosis. The liver specialists' own society called the approval a milestone, and they don't hand that word out.
Source: AASLDThe research interest here is real: by improving insulin sensitivity and easing the excess androgens behind PCOS, GLP-1s are showing early reports of more regular cycles and better metabolic markers in published research. But I'll say it plainly — this is not an FDA-approved use yet. Promising means promising.
Source: NCBI / peer-reviewed reviewResearchers are exploring whether GLP-1s' anti-inflammatory and insulin-lowering effects could help the metabolic side of endometriosis. File this under “genuinely interesting, ask me again in a year” — it's the earliest-stage item on this page, and I'd be doing you a disservice to oversell it.
Source: ESSIFor women in our forties and early fifties, clinicians are increasingly using GLP-1s off-label for the metabolic shift hormones drive — the insulin resistance, the weight that stopped responding, the energy crash. Off-label isn't a dirty word, but it does mean the conversation with a licensed provider matters more, not less.
Source: U.S. NewsThe pairing spreading through compounded women's-health practices: tirzepatide for the metabolic side, NAD+ for cellular-energy support. Full honesty from me on this one: the patient reports are loud, the clinical evidence is still early, and the blend is not FDA-approved. I watch this space closely — that's different from being sold on it.
These advances span the GLP-1 drug class; compounded tirzepatide is not FDA-approved for these conditions. Always talk to a licensed provider about what's right for you.
Here's the finding I keep coming back to: pooled trial evidence reviewed at OneDayMD points to roughly a 20% reduction in major cardiac events among GLP-1 users — and the benefit shows up even with modest weight loss. My read: tirzepatide is a cardiometabolic therapy that happens to help with weight, not a diet aid with side benefits. That reframe changes how you think about sticking with it.
The research summarized by Harvard Science Review suggests a meaningful share of GLP-1 weight loss can be lean mass — muscle — which is why clinicians now pair treatment with protein targets and strength work. What I'd do with that: treat protein like a prescription. You carry car seats, groceries, and occasionally a sleeping 60-pound child. The goal is feeling stronger, not just smaller.
NPR's reporting on the people who don't respond strongly to GLP-1s is quietly one of the most useful stories in this space: their biology is pushing researchers toward precision approaches — right drug, right dose, right patient. If the first dose plan didn't work for you, that's data, not failure. It's also exactly the kind of tailoring a careful provider should be doing with you.
For the millions of women managing PCOS — many of whom were handed a birth-control script and a “just lose weight” twenty years ago — the peer-reviewed work on GLP-1s, insulin, and androgens is the most-watched story in this class. Early reports show improved cycles and metabolic markers. My honest take: hopeful, not proven, and still off-label — which makes the licensed-clinician conversation the whole ballgame.
Every claim above traces to a source you can click — the FDA, specialty societies, peer-reviewed journals, or named outlets. I write my own analysis; I don't republish anyone else's. I keep “approved” and “investigational” in separate boxes, I update this page when the evidence moves, and when I get something wrong, I fix it and say so. And none of it is medical advice — my job is helping you ask better questions; a licensed provider's job is answering them. More about how I work →